Back

Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD

Ohene-Marfo, P.; Mohammed, S.; Jiang, C.; Bhaskaran, S.; Georgescu, C.; John, M.; Pham, K.; Tran, A.; Rao, C. V.; Gyu Oh, T.; Kinter, M.; Freeman, W. M.; Houchen, C.; Wren, J. D.; Deepa, S.

2025-11-30 cancer biology
10.1101/2025.11.26.690789 bioRxiv
Show abstract

Background and AimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatocellular carcinoma (HCC), particularly in obesity. Mixed Lineage Kinase Domain Like (MLKL), the effector of proinflammatory cell death pathway necroptosis, is consistently elevated in human and experimental MASLD, yet the hepatocyte-specific role of MLKL in the neoplastic progression of MASLD to HCC in obesity is unknown. Approach and ResultsWe used a long-term WD-induced, MASLD-driven HCC model in which mice develop liver cancer at ages comparable to human HCC onset. Hepatocyte-specific MLKL knockout (MlklHepKO) mice were generated to define MLKLs liver-intrinsic function. WD robustly induced hepatic MLKL, whereas necroptosis markers were undetectable. MLKL loss did not alter WD-induced inflammation, fibrosis, or liver injury but markedly increased lipid droplet accumulation. Strikingly, MlklHepKO mice developed significantly fewer and smaller tumors with reduced stemness markers (DCLK1, OCT4). Transcriptomic analysis revealed upregulation of mitochondrial oxidative phosphorylation pathways in WD-fed MlklHepKO livers. WD suppressed the mitochondrial fusion protein and tumor suppressor Mfn2, while MLKL deficiency restored its expression. In HepG2 cells, MLKL knockdown or inhibition reduced proliferation and clonogenicity and enhanced oxidative metabolism. Human HCC datasets and tissue microarrays showed elevated MLKL in tumors and its association with poor survival. ConclusionsHepatocyte MLKL drives MASLD-driven HCC progression by an intrinsic, non-necroptotic mechanism. The mechanism involves MLKL-mediated suppression of the Mfn2 tumor suppressor protein, impaired mitochondrial respiration, and increase in both tumor cell proliferation and tumor stemness. All together these data position MLKL as a novel, druggable target in MASLD-associated HCC. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=109 SRC="FIGDIR/small/690789v1_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@d670b5org.highwire.dtl.DTLVardef@818beaorg.highwire.dtl.DTLVardef@108e01forg.highwire.dtl.DTLVardef@1b218e1_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGRAPHICAL ABSTRACT:C_FLOATNO Graphical illustration of the proposed mechanism of the role of MLKL in WD-induced MASLD driven HCC. C_FIG

Published in Hepatology (predicted rank #3) · training set

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.